Answers are grounded in this paper and cite their sources.
Retrospective cohort study compares perinatal outcomes in fetuses with macrocystic CPAM treated with thoracoamniotic shunting or managed expectantly, highlighting significant differences.
OBJECTIVE: Describe prenatal imaging characteristics, perinatal and postnatal outcomes in fetuses with isolated macrocystic congenital pulmonary airway malformations (CPAM) undergoing thoracoamniotic shunting (TAS) and expectant management. METHODS: Retrospective cohort study of 123 fetuses with isolated macrocystic CPAM managed at the Ontario Fetal Center (1998-2024). Prenatal ultrasound features, perinatal outcomes, and postnatal surgical data were described for fetuses undergoing TAS and expectantly managed. Predictors of mortality were assessed in the TAS group. RESULTS: TAS was performed in 30/123 (24%) of cases. Shunted fetuses had higher CPAM volume ratio (CVR) (1.5 vs. 0.5), larger cyst diameter (3.4 vs. 1.0 cm), mediastinal shift (58% vs. 7%), and hydrops (16.7% vs. 0%). Lesion size decreased after TAS in 80% of cases; however, survival was lower (85% vs. 100), and preterm delivery was more frequent (24% vs. 7%). Among shunted cases, CVR > 2 or persistent hydrops were associated with perinatal mortality. Neonatal respiratory support was required more often following TAS (86% vs. 25%). Most infants underwent postnatal resection, occurring earlier after TAS (0.1 vs. 7.0 months). CONCLUSIONS: Macrocystic CPAM represents a high-risk subtype of congenital lung malformations, with a substantial proportion requiring fetal intervention, neonatal respiratory support, and postnatal surgical resection. These findings support tertiary surveillance and delivery.
No takes yet. Share an insight, caveat, or question.
Carmant et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: